Mineralys Therapeutics, Inc. (MLYS) Misses Q4 EPS by 27c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.98), $0.27 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• HSBC Upgrades Bid Corp Ltd (BID:SJ) to Buy
• HSBC Upgrades Merck KGaA (MRK:GR) (MKGAF) to Buy